<DOC>
	<DOCNO>NCT00619827</DOCNO>
	<brief_summary>The objective study assess effect grass pollen extract SLIT tablet Rhinoconjunctivitis Total Symptom Score ( RTSS ) six rhinoconjunctivitis symptom response grass pollen challenge one week , one , two four month treatment patient suffer Seasonal Allergic Rhinoconjunctivitis ( SAR ) due grass pollen .</brief_summary>
	<brief_title>Efficacy Safety Sublingual Tablets Grass Pollen Allergen Extract</brief_title>
	<detailed_description>The purpose study determine whether SLIT tablet effective symptom allergic rhinitis compare placebo patient suffer allergic rhinitis grass pollen expose allergen chamber also determine onset action SLIT tablets allergic rhinitis symptom .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>Male female outpatient 1850 year old grass pollen rhinoconjunctivitis least 2 year . positive specific skin prick test specific IgE dosage level least 0.70 kU/L screen . write consent positive response baseline challenge test ( RTSS reach 7 one timepoint least baseline challenge ) Allergic rhinoconjunctivitis due cosensitisation , likely significantly change symptom subject throughout study Asthma require treatment shortacting beta2 inhaled agonist . Desensitisation treatment grass pollen previous five year current immunotherapy another allergen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Sublingual immunotherapy</keyword>
	<keyword>Rhinitis</keyword>
	<keyword>Conjunctivitis</keyword>
	<keyword>Allergen challenge</keyword>
	<keyword>Allergen exposition chamber</keyword>
	<keyword>Grass pollen tablet</keyword>
	<keyword>Allergic rhinoconjunctivitis</keyword>
</DOC>